Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $67.10 million. The enterprise value is $50.14 million.
| Market Cap | 67.10M |
| Enterprise Value | 50.14M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 6.12 million shares outstanding. The number of shares has increased by 44.35% in one year.
| Current Share Class | 6.12M |
| Shares Outstanding | 6.12M |
| Shares Change (YoY) | +44.35% |
| Shares Change (QoQ) | +58.89% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 93.56% |
| Float | 4.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.86 |
| Forward PS | 6.80 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.53
| Current Ratio | 0.53 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.39% |
| Return on Invested Capital (ROIC) | -200.91% |
| Return on Capital Employed (ROCE) | 260.39% |
| Weighted Average Cost of Capital (WACC) | 18.34% |
| Revenue Per Employee | $484,093 |
| Profits Per Employee | -$772,062 |
| Employee Count | 162 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.92% in the last 52 weeks. The beta is 2.27, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -94.92% |
| 50-Day Moving Average | 10.56 |
| 200-Day Moving Average | 31.23 |
| Relative Strength Index (RSI) | 54.76 |
| Average Volume (20 Days) | 173,977 |
Short Selling Information
The latest short interest is 1.34 million, so 21.90% of the outstanding shares have been sold short.
| Short Interest | 1.34M |
| Short Previous Month | 1.44M |
| Short % of Shares Out | 21.90% |
| Short % of Float | 30.45% |
| Short Ratio (days to cover) | 5.60 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $78.42 million and -$125.07 million in losses. Loss per share was -$40.17.
| Revenue | 78.42M |
| Gross Profit | 78.42M |
| Operating Income | -107.01M |
| Pretax Income | -125.16M |
| Net Income | -125.07M |
| EBITDA | -107.00M |
| EBIT | -107.01M |
| Loss Per Share | -$40.17 |
Balance Sheet
The company has $57.03 million in cash and $40.07 million in debt, with a net cash position of $16.96 million or $2.77 per share.
| Cash & Cash Equivalents | 57.03M |
| Total Debt | 40.07M |
| Net Cash | 16.96M |
| Net Cash Per Share | $2.77 |
| Equity (Book Value) | -94.03M |
| Book Value Per Share | -15.39 |
| Working Capital | -65.06M |
Cash Flow
| Operating Cash Flow | -162.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 18,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -162.63M |
| FCF Per Share | -$26.59 |
Margins
Gross margin is 100.00%, with operating and profit margins of -136.46% and -159.49%.
| Gross Margin | 100.00% |
| Operating Margin | -136.46% |
| Pretax Margin | -159.60% |
| Profit Margin | -159.49% |
| EBITDA Margin | -136.43% |
| EBIT Margin | -136.46% |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -44.35% |
| Shareholder Yield | -44.35% |
| Earnings Yield | -366.22% |
| FCF Yield | -242.38% |
Analyst Forecast
The average price target for Gossamer Bio is $83.40, which is 660.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $83.40 |
| Price Target Difference | 660.26% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 13.37% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 11, 2026. It was a reverse split with a ratio of 1:80.
| Last Split Date | Sep 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:80 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |